Embodiments of screening methods for determining test agents effective for modifying the appearance of pigmented skin are provided. The screening method may comprise the steps of contacting a cell, a cell culture, or bulk cells with the test agent, wherein the cell, the cell culture, or the bulk cells comprise ADR1 receptors, and determining based on the binding interaction of the test agent with the ADR1 receptors whether the test agent is an effective ADR1 receptor antagonist suitable for modifying the appearance of pigmented skin, wherein a test agent is considered to be an effective ADR1 receptor antagonist when it defines a half maximal inhibitory concentration of less than about 1000 ppm.

Novel benzamide compounds including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa are described. Compositions containing such compounds are also described. The compounds and compositions are useful in vitro or in vivo for preventing or treating coagulation disorders.

Novel benzamide compounds including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa are described. Compositions containing such compounds are also described. The compounds and compositions are useful in vitro or in vivo for preventing or treating coagulation disorders.

Disclosed are modulators of the human relaxin receptor 1, for example, of formula (I), wherein A, R.sup.1, and R.sup.2 are as defined herein, that are useful in treating mammalian relaxin receptor 1 mediated facets of human health, e.g., cardiovascular disease. Also disclosed is a composition comprising a pharmaceutically suitable carrier and at least one compound of the disclosure, and a method for therapeutic intervention in a facet of mammalian health that is mediated by a human relaxin receptor 1. ##STR00001##

The present invention relates to a process for the preparation of 4-aminobenzoamidine (4-AMBA) salts of general formula (I)

##STR00001##

preferably the salts thereof with hydrochloric or hydrobromic acid, particularly preferred the dichloride salt.

The present invention relates to a process for the preparation of 4-aminobenzoamidine (4-AMBA) salts of general formula (I)

##STR00001##

preferably the salts thereof with hydrochloric or hydrobromic acid, particularly preferred the dichloride salt.

The present invention includes substituted 3,3bis(phenoxymethyl)-1,1-biphenyl compounds, analogues thereof, and compositions comprising the same, that can be used to treat or prevent hepatitis B virus (HBV) and/or hepatitis D virus (HDV) infections in a patient.

The present invention relates to a process for the preparation of 4-aminobenzoamidine (4-AMBA) salts of general formula (I) ##STR00001##
preferably the salts thereof with hydrochloric or hydrobromic acid, particularly preferred the dichloride salt.

The present invention relates to a process for the preparation of 4-aminobenzoamidine (4-AMBA) salts of general formula (I) ##STR00001##
preferably the salts thereof with hydrochloric or hydrobromic acid, particularly preferred the dichloride salt.

The present invention relates to halogen-substituted phenoxyphenylamidines of the general formula (I), to a process for their preparation, to the use of the amidines according to the invention for controlling unwanted microorganisms and also to an agrochemical formulation for this purpose, comprising the halogen-substituted phenoxyphenylamidines according to the invention. Furthermore, the invention relates to a method for controlling unwanted microorganisms by applying the compounds according to the invention to the microorganisms and/or their habitat.